SIGN UP
LOG IN
A
ATYR
Atyr Pharma Inc
3.35
-0.10-2.90%After Hours: 3.390 +0.040 +1.19%19:59 04/25 EDT
OPEN/PREV CLOSE3.420/3.450
TODAY RANGE3.290-3.470
VOL633.28K
MARKET CAP297.68M
52 WEEK RANGE1.420-4.660
AVG VOL (3M)1.42M
% TURNOVER0.71%
TURNOVER--
P/E (TTM)-3.8859
% RANGE5.22%
EPS(TTM)-0.8621
P/E(FORWARD)-4.9265
P/B4.021
BVPS0.8332
DIVIDEND--
P/S1,196.43
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP291.01M
SHARES OUTSTANDING88.86M
NEXT EARNINGS04/30-05/05
FREE FLOAT86.87M
LOT SIZE1
EX-DIV DATE07/01/2019
News
Press Releases
Financial Reports
Profile
Benzinga·2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press release·04/07 11:55
ATYR Pharma, Inc. (ATYR) Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
TipRanks·03/31 10:56
Piper Sandler Remains a Buy on aTyr Pharma (ATYR)
Reuters·03/27 20:00
ATYR PHARMA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
TipRanks·03/27 11:26
Confident Buy Rating for aTyr Pharma Amidst Promising Phase 3 Study Insights
TipRanks·03/26 12:16
aTyr names Dalia Reyes head of commercial, global efzofitimod franchise
NASDAQ·03/19 13:40
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Seeking Alpha·03/14 19:10
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
Dow Jones·03/14 10:59
aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Benzinga·03/14 10:48
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Press release·03/13 22:41
ATYR Pharma, Inc. (ATYR) Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
Seeking Alpha·03/13 20:13
aTyr Pharma GAAP EPS of -$0.18 beats by $0.05
Benzinga·03/13 20:11
aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.